HemoGenix(R) Launches HALO(TM) 384HT, the First Ever High Throughput Predictive Stem Cell Hemotoxicity Screening Platform

HALO(TM)-384HT Significantly Advances the Entire Line of Toxicity Assays

Developed by HemoGenix(R) and Initiates a New Era of 'In vitro

Cross-Platform Comparative Toxicity Testing'(TM)



Jun 22, 2006, 01:00 ET from HemoGenix, Inc.

    COLORADO SPRINGS, Colo., June 22 /PRNewswire/ -- HemoGenix(R), Inc is
 proud to announce the first ever, true high-throughput stem cell
 hemotoxicity predictive testing platform using a 384-well plate format for
 both contract research services and a comprehensive assay kit product line.
     In 2002, HemoGenix(R) was the first company to provide the
 biotechnology and pharmaceutical industry with the HALO(TM) Platform, a
 non-subjective and fully standardized ATP-based in vitro luminescence assay
 system designed to routinely determine the effects of drugs on stem cells
 of the blood-forming system. Since its founding in 2000, the HemoGenix(R)
 Premise has been that the highest predictive value in toxicity testing,
 safety and risk assessment for new drug candidates and other agents can
 only be achieved using high- performance in vitro assays employing fresh,
 primary human target cells as surrogate tests for real situations in human
 clinical trials. This premise was substantiated through a peer reviewed
 article published in Toxicological Sciences entitled "Validation and
 Development of a Predictive Paradigm for Hemotoxicity Using a
 Multi-functional Bioluminescence Colony-Forming Proliferation Assay" in
 2005 (vol. 87, pp. 427-441).
     Originally developed and validated with the financial backing of a SBIR
 grant from the National Cancer Institute, the HALO(TM) Platform was
 designed to test for potential toxicity to stem cells of the blood-forming
 system using primary human bone marrow, peripheral blood or umbilical cord
 blood target cells at any stage in the drug development pipeline. Further
 developments have allowed the HALO(TM) Platform to detect a total of 14
 separate cell populations involved in the blood-forming system that can be
 detected not only on human cells, but also those animal species used in
 pre-clinical drug testing, notably non-human primate, dog, rat and mouse.
     This unique and patented technology has now been further developed from
 a 96- to a 384-well plate format, thereby providing biotechnology and
 pharmaceutical companies with a true high-throughput (HT) and predictive
 platform for screening large numbers of compounds for potential
 hemotoxicity during the drug discovery screening stage.
     In addition to HALO(TM), HemoGenix(R) has also developed the
 LUMENESC(TM) Platform to detect toxicity to the mesenchymal stem cell
 system, responsible for producing muscle, skeletal, fat and even nerve
 cells, and STEMTox(TM) for the detection of toxicity to multiple
 proliferating cell types, including primary cells from different organs and
 tissues as well as embryonic stem and germ cells and even transformed cell
 lines.
     The HALO(TM)-384HT Predictive Hemotoxicity Platform, now joins forces
 with LUMENESC(TM) 384HT Tox and STEMTox(TM) 384HT to detect and measure
 potential toxicity to more than 50 cell types from 14 different cell
 systems of the body using a single ATP-based luminescence signal detection
 system. This powerful and unique line of high-throughput, fully
 standardized assays is called "In vitro Cross-Platform Comparative Toxicity
 Testing"(TM).
     Ivan Rich, PhD, Founder and CEO of HemoGenix(R), Inc said that
 "although we are continually improving our present technology and
 developing new technology, the HALO(TM)-384HT Predictive Hemotoxicity
 Platform and "In vitro Cross-Platform Comparative Toxicity Testing"(TM) is
 the culmination of our primary goal, namely to provide biotechnology and
 pharmaceutical companies and investigators in other research areas and
 institutions the means to rapidly and easily test and directly compare the
 effects of different agents on multiple cell types simultaneously in a
 non-subjective, fully standardized and high-throughput manner."
     The HALO(TM)-384HT Platform and "In vitro Cross-Platform Comparative
 Toxicity Testing"(TM) will be launched at the upcoming 6th International
 Conference on Early Toxicity Screening, June 22-23, 2006 in Seattle, WA and
 at the International Society of Stem Cell Research (ISSCR), June 29-July 1,
 2006 in Toronto, Canada.
     More information is available at www.hemogenix.com and info@hemogenix.com
 
     CONTACT:  George Down
               719-264-6250
               gdown@hemogenix.com
 
 

SOURCE HemoGenix, Inc.
    COLORADO SPRINGS, Colo., June 22 /PRNewswire/ -- HemoGenix(R), Inc is
 proud to announce the first ever, true high-throughput stem cell
 hemotoxicity predictive testing platform using a 384-well plate format for
 both contract research services and a comprehensive assay kit product line.
     In 2002, HemoGenix(R) was the first company to provide the
 biotechnology and pharmaceutical industry with the HALO(TM) Platform, a
 non-subjective and fully standardized ATP-based in vitro luminescence assay
 system designed to routinely determine the effects of drugs on stem cells
 of the blood-forming system. Since its founding in 2000, the HemoGenix(R)
 Premise has been that the highest predictive value in toxicity testing,
 safety and risk assessment for new drug candidates and other agents can
 only be achieved using high- performance in vitro assays employing fresh,
 primary human target cells as surrogate tests for real situations in human
 clinical trials. This premise was substantiated through a peer reviewed
 article published in Toxicological Sciences entitled "Validation and
 Development of a Predictive Paradigm for Hemotoxicity Using a
 Multi-functional Bioluminescence Colony-Forming Proliferation Assay" in
 2005 (vol. 87, pp. 427-441).
     Originally developed and validated with the financial backing of a SBIR
 grant from the National Cancer Institute, the HALO(TM) Platform was
 designed to test for potential toxicity to stem cells of the blood-forming
 system using primary human bone marrow, peripheral blood or umbilical cord
 blood target cells at any stage in the drug development pipeline. Further
 developments have allowed the HALO(TM) Platform to detect a total of 14
 separate cell populations involved in the blood-forming system that can be
 detected not only on human cells, but also those animal species used in
 pre-clinical drug testing, notably non-human primate, dog, rat and mouse.
     This unique and patented technology has now been further developed from
 a 96- to a 384-well plate format, thereby providing biotechnology and
 pharmaceutical companies with a true high-throughput (HT) and predictive
 platform for screening large numbers of compounds for potential
 hemotoxicity during the drug discovery screening stage.
     In addition to HALO(TM), HemoGenix(R) has also developed the
 LUMENESC(TM) Platform to detect toxicity to the mesenchymal stem cell
 system, responsible for producing muscle, skeletal, fat and even nerve
 cells, and STEMTox(TM) for the detection of toxicity to multiple
 proliferating cell types, including primary cells from different organs and
 tissues as well as embryonic stem and germ cells and even transformed cell
 lines.
     The HALO(TM)-384HT Predictive Hemotoxicity Platform, now joins forces
 with LUMENESC(TM) 384HT Tox and STEMTox(TM) 384HT to detect and measure
 potential toxicity to more than 50 cell types from 14 different cell
 systems of the body using a single ATP-based luminescence signal detection
 system. This powerful and unique line of high-throughput, fully
 standardized assays is called "In vitro Cross-Platform Comparative Toxicity
 Testing"(TM).
     Ivan Rich, PhD, Founder and CEO of HemoGenix(R), Inc said that
 "although we are continually improving our present technology and
 developing new technology, the HALO(TM)-384HT Predictive Hemotoxicity
 Platform and "In vitro Cross-Platform Comparative Toxicity Testing"(TM) is
 the culmination of our primary goal, namely to provide biotechnology and
 pharmaceutical companies and investigators in other research areas and
 institutions the means to rapidly and easily test and directly compare the
 effects of different agents on multiple cell types simultaneously in a
 non-subjective, fully standardized and high-throughput manner."
     The HALO(TM)-384HT Platform and "In vitro Cross-Platform Comparative
 Toxicity Testing"(TM) will be launched at the upcoming 6th International
 Conference on Early Toxicity Screening, June 22-23, 2006 in Seattle, WA and
 at the International Society of Stem Cell Research (ISSCR), June 29-July 1,
 2006 in Toronto, Canada.
     More information is available at www.hemogenix.com and info@hemogenix.com
 
     CONTACT:  George Down
               719-264-6250
               gdown@hemogenix.com
 
 SOURCE HemoGenix, Inc.